Physician profile
Michael Balm
NPI 1164593646
$1,225.32
in general payments reported to CMS, 2019-2025
24 companies · $98.35 in 2025
The $98.35 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $13.06 · 2021: $365 · 2022: $217 · 2023: $153 · 2024: $227 · 2025: $98.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $478.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $168.42 | 2022-2025 | Ubrelvy |
| Novartis Pharmaceuticals Corporation | $134.06 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $133.97 | 2021-2022 | |
| Argenx US, INC. | $132.36 | 2022-2024 | Vyvgart Hytrulo |
| Jazz Pharmaceuticals INC. | $71.11 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $60.27 | 2021 | |
| Alexion Pharmaceuticals, INC. | $57.55 | 2019-2021 | |
| Genzyme Corporation | $51.07 | 2019-2023 | |
| Acorda Therapeutics, INC | $45.20 | 2021-2023 | Inbrija, Ampyra |
| Greenwich Biosciences, INC. | $43.95 | 2019-2021 | |
| Celgene Corporation | $39.16 | 2021 | |
| Advanced Respiratory, INC | $35.88 | 2019 | |
| Allergan, INC. | $33.99 | 2020-2021 | |
| Emd Serono, INC. | $33.70 | 2019 | |
| Pfizer INC. | $29.93 | 2019-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $24.51 | 2023 | Nalu Neurostimulation System |
| Sumitomo Pharma America, INC. | $20.53 | 2023 | Aptiom |
| Immedica Pharma US, INC. | $18.63 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $16.83 | 2022 | |
| Avion Pharmaceuticals | $16.40 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.21 | 2021 | |
| Boston Scientific Corporation | $15.68 | 2021 | |
| Horizon Therapeutics Plc | $14.21 | 2022 | |
| Zogenix INC. | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Balm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.